CAP Laboratory Improvement Programs. Clinical Consequences of Specimen Rejection
|
|
- Janis Garrett
- 6 years ago
- Views:
Transcription
1 CAP Laboratory Improvement Programs Clinical Consequences of Specimen Rejection A College of American Pathologists Q-Probes Analysis of 78 Clinical Laboratories Donald S. Karcher, MD; Christopher M. Lehman, MD Context. Clinical laboratory specimens may be rejected as unsuitable for analysis for a variety of reasons and specimen rejection may have significant clinical consequences. Objective. To quantify the clinical consequences of specimen rejection and determine the impact of laboratories policies and practices on these consequences. Design. Participants prospectively reviewed consecutive blood and urine specimens submitted to the chemistry and/or hematology laboratories to identify rejected specimens. For each rejected specimen, the patient s age, specimen type, testing priority, rejection reason, time from specimen receipt to receipt of recollected/relabeled specimen, recollection method, and test result time were recorded. Specimen/test abandonment was determined by failure to recollect or relabel a rejected specimen. Each laboratory s policy regarding relabeling of incorrectly labeled specimens was recorded, along with how many relabeled specimens were subsequently discovered to be mislabeled. Results. Specimen rejection led to a (1) high rate of specimen recollection, (2) delay in result availability (median of 65 minutes), and (3) high rate of specimen/ test abandonment. Longer test result delay was associated with higher hospital bed size; and higher test abandonment rate, with failure of the laboratory to request specimen recollection. Relabeling of incorrectly labeled specimens was found to be of little benefit and was associated with a substantial percentage of subsequently mislabeled specimens. Conclusions. Specimen rejection has significant clinical consequences, including patient discomfort, significant delay in result availability, and high rate of specimen/test abandonment. Allowing routine relabeling of incorrectly labeled specimens is a dangerous practice, with little measureable benefit and with an increased risk to patient safety. (Arch Pathol Lab Med. 2014;138: ; doi: /arpa CP) Specimens submitted to the clinical laboratory may be rejected as unsuitable for analysis for a variety of reasons, including inaccurate or inadequate labeling of the specimen and defects in specimen quality or quantity. Specimens submitted to the chemistry and hematology laboratories are typically rejected at an approximate mean rate of 1.0% or less of all specimens submitted, with the rate usually higher for inpatients and patients in the emergency department than for outpatients. 1 4 Specimen rejection may have significant consequences for patients and their clinical management. Patients whose specimens are rejected are frequently subjected to repeated specimen collection, resulting in inconvenience, the discomfort of repeated phlebotomy or other collection procedures, and/or the potential need for blood transfusion due to excessive iatrogenic blood loss. Specimen rejection and the need for specimen recollection or correction also ultimately lead to a delay in specimen analysis and the availability of test results and may lead to abandonment of the test(s) requested. The prolonged turnaround time is clinically most significant for tests ordered with a stat testing priority, but similar delays may also impact routine and other nonstat tests. This study was designed to quantify the effect of laboratory specimen rejection on the need to recollect specimens, the delay in test result availability, and the rate of test abandonment, and to determine the impact on test result availability of the (1) reason for specimen rejection, (2) detection method used for mislabeled specimens, and (3) the laboratory s policy regarding resolution of improperly labeled specimens. In addition, an attempt was made to measure the accuracy of relabeling of incorrectly labeled specimens, if allowed by the laboratory. Accepted for publication October 7, From the Department of Pathology, The George Washington University Medical Center, Washington, DC (Dr Karcher); and the Department of Pathology, University of Utah School of Medicine, Salt Lake City (Dr Lehman). MATERIALS AND METHODS Study Design The authors have no relevant financial interest in the products or companies described in this article. Participants prospectively reviewed consecutive blood and urine Reprints: Donald S. Karcher, MD, Department of Pathology, The specimens submitted to the central chemistry and/or hematology George Washington University Medical Center, 2100 W Pennsylvania (including coagulation) laboratory sections to identify specimens Ave, NW, 5th Floor, Suite 5027, Washington, DC ( dkarcher@mfa.gwu.edu). that were rejected for any reason. This process was conducted on all laboratory shifts until 80 rejected specimens that fit the study Arch Pathol Lab Med Vol 138, August 2014 Specimen Rejection Karcher & Lehman 1003
2 Table 1. Definitions of Terms Provided to Participants Test accession: A test order that resulted in a unique laboratory accession number. Rejected specimen: A specimen that was found for any reason to be unsuitable for analysis before initiation of testing or a specimen found, before or after completion of testing, to be mislabeled or otherwise inappropriate as a result of comparison of the specimen label to the requisition form or electronic test order, or comparison of the current test results to previous laboratory results for the same patient (delta check analysis) or to the patient s clinical status. Improperly labeled specimen: A specimen that was (1) unlabeled, (2) incompletely labeled (does not include the minimum information required by institutional guidelines), (3) labeled with information not in adequate agreement with the accompanying requisition form or electronic test order, or (4) mislabeled (ie, found to not be from the intended patient, by any method of detection). Inappropriate or inadequate specimen: A specimen found to be unsuitable for analysis as a result of (1) hemolysis, (2) unintended clotting, (3) inadequate quantity, (4) inappropriate anticoagulant and/or collection container, (5) improper method of collection, (6) excessive time from collection to receipt in the laboratory, or (7) inappropriate storage conditions before receipt in the laboratory. Laboratory check of specimen label ( lab check ): Means of detecting mislabeled specimens by laboratory personnel proactively comparing the specimen label to the accompanying requisition form or electronic test order. Delta check: Means of detecting mislabeled specimens by laboratory personnel and/or the laboratory information system comparing test results to previous results for the same patient. Laboratory correlation with clinical picture ( clinical picture lab ): Means of detecting mislabeled specimens by laboratory personnel proactively comparing test results to the patient s clinical picture. Feedback from patient s clinical care team ( feedback from caregiver ): Detection of a mislabeled specimen by feedback received from the patient s clinical care team indicating that the test result(s) is(are) inappropriate for the patient s clinical picture. Note: Although this would occur after initial test result(s) had already been reported, this was still considered rejection of the original specimen and included in the study. Corrected specimen: A specimen found to be improperly labeled and then allowed to be relabeled correctly without requiring recollection. Recollected specimen: A specimen recollected in direct response to rejection of a specimen previously collected for the same test(s). Note: For the purposes of this study, any specimen recollected more than 6 hours after a specimen was rejected was not considered to be in direct response to the previous rejection and was excluded. Abandoned specimen: When a specimen was rejected and neither a recollected nor relabeled specimen was received within 6 hours of the time of rejection, the original specimen/test was considered to be abandoned. Laboratory-abandoned specimen: Specimen abandoned (see Abandoned specimen above) when the laboratory did not request a recollected or relabeled specimen. Provider-abandoned specimen: Specimen abandoned (see Abandoned specimen above) when the provider did not provide a recollected or relabeled specimen after having been requested to do so by the laboratory. inclusion criteria were identified or until 6 weeks elapsed, whichever came first. Definitions of terms provided to participants are listed in Table 1. Specimens included in the study were those received from inpatients and emergency department patients older than 6 months for on-site analysis. The following specimen types were excluded from the study: point-of-care, blood bank, bone marrow, specimens received in the form of pre-prepared smears, and specimens submitted for highly specialized testing (ie, flow cytometry, molecular DNA/RNA, cytogenetic analysis). Participants provided the total number of chemistry and hematology accessions separately for the study period. For each rejected specimen included in the study, the following information was recorded: patient age, specimen type, laboratory testing section, test priority, time of specimen receipt and time of specimen rejection, rejection reason, detection method used for rejection due to improper labeling, whether or not a recollected or relabeled specimen was requested by the laboratory, time of recollected/ relabeled request, time of recollected/relabeled specimen receipt, recollection method for blood and urine specimens, if applicable, and result time. Participants were also asked to provide information regarding their laboratory s policies and practices in the following areas: presence of a detailed written policy regarding the detection and/or handling of rejected specimens, method(s) used to detect improperly labeled specimens, whether or not improperly labeled blood and/or urine specimens are allowed to be relabeled, and the nature of recommendation(s) made to providers when a specimen is rejected. Statistical Analysis Five performance indicators were calculated for this study: specimen rejection rate, median processing delay, percentage of laboratory-abandoned specimens, percentage of provider-abandoned specimens (see Table 1), and percentage of relabeled specimens subsequently determined to not be from the intended patient (wrong specimen in container). Median processing delay was defined as the interval between the original and recollected/ relabeled specimen receipt times. Individual associations between the first 4 performance indicators with demographic and practice variables were tested by using Kruskal-Wallis tests for discrete-valued independent variables and regression analysis for the continuous independent variables. The 2 abandoned rates were skewed so a log transformation was used for the regression-based analyses. Variables with significant associations for the individual associations (P,.10) were then included in a forward selection multivariate regression model. A significance level of.05 was used for the final multivariate models. All analyses were run by using SAS 9.1 (SAS Institute, Cary, North Carolina). RESULTS Table 2 lists the characteristics of the 78 institutions submitting data for this study. A total of 4794 rejected specimens were identified from accessions. Most of the participating institutions (94%) are located in the United States, with the remaining in Saudi Arabia (2), Canada, Jordan, and Spain. Of the participating institutions, 39% are teaching hospitals and 27% have pathology residency training programs. Table 3 illustrates the distribution of 4 of the 5 performance indicators among participants. The overall specimen rejection rate was 0.2%, with the 90th percentile at 0.1%, median at 0.3%, and 10th percentile at 1.5%. The overall median specimen processing delay due to specimen rejection was 65 minutes, with a median of 54 minutes for stat specimens and 88 minutes for nonstat specimens. Of the 4794 rejected specimens, 537 (11.2%) were abandoned by either the laboratory not requesting a recollected or relabeled specimen (laboratory abandoned) or by the 1004 Arch Pathol Lab Med Vol 138, August 2014 Specimen Rejection Karcher & Lehman
3 Table 3. Table 2. Institution Characteristics Count Percentage Occupied bed size Institution location City Rural Suburban Federal installation Government affiliation Nongovernmental Governmental, nonfederal Governmental, federal Institution type Voluntary, nonprofit hospital County hospital Nongovernmental, university hospital Proprietary hospital Veterans hospital State acute hospital Children s hospital Department of Defense Governmental, nonfederal university hospital Indian Health Service Private, independent laboratory System/integrated delivery network Distribution of Performance Indicators N All Institutions Percentiles 10th 25th Median (50th) 75th 90th Rate of specimen rejection, % Median specimen processing delay, min Laboratory-abandoned specimens, % Provider-abandoned specimens following laboratory request for correction/ recollection, % Table 4. Information Relating to the Rejected Specimens Included in This Study a Count Percentage Patient age, y Specimen type Blood Urine Laboratory testing location Chemistry Hematology Test priority Stat Nonstat Not applicable Rejection reason Inappropriate/inadequate specimen Improperly labeled Improper labeling detection method Laboratory check Feedback from caregiver Delta check Clinical picture laboratory Not applicable Other Response to specimen rejection Recollected specimen Abandoned specimen (neither recollected nor relabeled/corrected) Relabeled/corrected specimen Blood recollection method Phlebotomy Line draw Urine recollection method Urine cup Catheterization a See Table 1 for definition of terms. provider or caregiver team not complying with the laboratory request (provider abandoned). The median laboratory abandonment rate was 1.3%. The median provider abandonment rate was 5%. Nonstat and urine specimens were significantly more likely to be abandoned, with approximately equal likelihood for laboratory- and provider-abandoned specimens. Table 4 details information relating to the rejected specimens. A substantial majority (96.5%) of rejected specimens were blood, with essentially equal numbers of chemistry and hematology specimens. The reason for most rejected specimens (92.4%) was inappropriate/inadequate specimen. The remaining 7.6% were rejected owing to improper labeling. Regarding specimens found to be improperly labeled, most (73.6%) were detected by laboratory review ( lab check ), 9.9% by feedback from caregiver, and 9.1% by delta check (see Table 1). Most rejected specimens (87.7%) were ultimately recollected, 1.1% were relabeled/corrected, and 11.2% were abandoned (neither recollected nor relabeled/corrected). The first 4 performance indicators were tested for associations with institutional demographic and laboratory policy variables. A P value of less than.05 was considered statistically significant. Institutional and/or laboratory policy relationships were found with 3 of the first 4 performance indicators. No relationships were found with the rate of specimen rejection. The significant associations, detailed in Table 5, were as follows: longer specimen processing delays tended to occur in institutions with higher occupied bed size; higher rates of laboratory-abandoned specimens tended to occur in laboratories that communicate to the patient s caregiver that the specimen is rejected without providing any direction for specimen replacement; and higher rates of provider-abandoned specimens tended to occur in institutions that train pathology residents/fellows or Arch Pathol Lab Med Vol 138, August 2014 Specimen Rejection Karcher & Lehman 1005
4 Table 5. Statistically Significant Relationships Between 3 Performance Indicators and Demographic or Practice Variables No. of Institutions 10th Percentile Median 90th Percentile Median specimen processing delay, min Occupied bed size (P ¼.005) Rejected specimens abandoned by laboratory, % Laboratory only communicates that the specimen is rejected when reporting a rejected specimen to the patient s caregiver (P ¼.01) Yes No Rejected specimens abandoned by provider, % Laboratory trains pathology residents/fellows (P ¼.007) Yes No Laboratory allows any improperly labeled chemistry or hematology blood specimen to be relabeled without requiring the specimen to be recollected (P ¼.01) Yes No that do not allow improperly labeled chemistry or hematology blood specimens to be relabeled without requiring the specimen to be recollected. Table 6 summarizes responses received from participants regarding their policies and practices related to detection and resolution of rejected specimens. Of the participating laboratories, 45% reported that they allow improperly labeled blood specimens (see Table 1) to be relabeled (among these, 85% when incompletely labeled, 59% when mislabeled, and 38% when unlabeled). Likewise, 37% allow improperly labeled urine specimens to be relabeled (among these, 89% when incompletely labeled, 57% when mislabeled, and 36% when unlabeled). Regarding the laboratories that allow relabeling of specimens and the relabeled specimens included in this study, the following were found: (1) These laboratories reported no better performance regarding specimen processing delay, but a slightly lower rate of provider-abandoned specimens (see Table 5); (2) of the 51 improperly labeled specimens that were relabeled, 20 specimens (39%) were subsequently discovered to not be from the intended patient (wrong specimen in container). Of the 6 laboratories that reported the 20 relabeled specimens with wrong specimen in container, 4 allowed relabeling of unlabeled blood and/or urine specimens, and 2 stated that they did not allow relabeling of any improperly labeled specimens (ie, there was an apparent breach of policy). Among the 51 improperly labeled specimens allowed to be relabeled, there was no statistically significant difference in the rate of relabeling between stat and routine test priorities. COMMENT Defects in laboratory specimens that result in specimen rejection are a cause of inconvenience and discomfort to patients, lead to a delay in the availability of often critical laboratory results, and, if the methods used to detect specimen defects are not effective, may also represent a major compromise of patient safety. To address the potential harm to patients from misidentification, including mislabeling of laboratory specimens, the Joint Commission 5 has for the past several years designated accurate patient identification as one of its national patient safety goals. This study clearly documents the consequences of laboratory specimen defects and resulting specimen rejection. Prospective analysis performed by 78 institutions of a total of specimen accessions revealed an overall specimen rejection rate of 0.2%. This is generally in line with the rate reported in past studies of specimen rejection, 1 4 which have typically shown rates of less than 0.3% and up to 0.75%, with lower rejection rates reported in more recent studies. 3,4 The first and most direct consequence of specimen rejection is the need to collect a new specimen from the patient. In this study, 86.8% of rejected blood specimens led to repeated phlebotomy. Likewise, 13.8% of rejected urine specimens required recatheterization of the patient to collect a new urine sample. Both of these repeated procedures are associated with inconvenience and discomfort for the patient, and both introduce the potential for patient complications. Another well-known consequence of specimen rejection is a delay in the performance and reporting of the results of the ordered tests. In this study, the median specimen processing delay was 65 minutes, with a range of 41 minutes (90th percentile) to 93 minutes (10th percentile). The median processing delay was longer for tests with routine priority (88 minutes) but was still 54 minutes for stat tests. This indicates that delays in availability of urgent and sometimes critical test results of nearly a full hour are commonly seen when stat specimens must be rejected. An interesting association with even longer specimen processing delay (median ¼ 91 minutes) was hospital occupied bed size, specifically with bed size of greater than 450 beds. No definite explanation for this association was apparent; however, this may be a function of the greater complexity of very large hospitals, which could contribute to less effective communication among patient care staff members and slower response time to special requests, such as for recollection of a rejected laboratory specimen. Although not specifically assessed in this study, longer delays in test result availability in the largest hospitals, where the clinical acuity 1006 Arch Pathol Lab Med Vol 138, August 2014 Specimen Rejection Karcher & Lehman
5 Table 6. Laboratory Policies and Practices Relating to Rejected Specimens Count Percentage Does your laboratory have a detailed written policy/procedure regarding the detection and/or handling of the following? a (N ¼ 74) Improperly labeled (including mislabeled) specimens Inappropriate/inadequate specimens Neither What methods are used by your laboratory to detect improperly labeled (including mislabeled) specimens? a (N ¼ 75) Laboratory check of specimen label Delta check Feedback from patient s clinical care team Laboratory correlation with the clinical picture If you indicated delta check above, which method is used in your laboratory to perform delta checks? Automated/preprogrammed comparison using laboratory information system Both manual and automated comparison Manual comparison by laboratory personnel Does your laboratory allow any improperly labeled blood specimens submitted to the central chemistry or hematology laboratories to be relabeled correctly without requiring the specimen to be recollected? Yes No If blood specimens are allowed to be relabeled correctly, for which of the following circumstances? a (N ¼ 34) Incompletely labeled specimens Mislabeled specimens Unlabeled specimens Does your laboratory allow any improperly labeled urine specimens submitted to the central chemistry or hematology laboratories to be relabeled correctly without requiring the specimen to be recollected? Yes No If urine specimens are allowed to be relabeled correctly, for which of the following circumstances? a (N ¼ 28) Incompletely labeled specimens Mislabeled specimens Unlabeled specimens When your laboratory reports a rejected chemistry or hematology specimen to a patient s caregiver, what may be communicated to the caregiver? a (N ¼ 74) The specimen is rejected The specimen is rejected, please recollect The specimen is rejected, please come to laboratory to correct labeling defect Were any relabeled specimens encountered in this study subsequently discovered, by any means, to not be from the intended patient? Yes No If any relabeled specimens in this study were subsequently discovered to not be from the intended patient, how many were there? a Multiple responses allowed. of patients is often higher, may have an even greater negative impact on patient safety and on the delivery of care to a larger number of critically ill patients. An additional significant consequence of laboratory specimen rejection is abandonment of the ordered test(s). Such abandonment may occur when the laboratory fails to request recollection or relabeling/correction of a defective specimen (laboratory abandonment) or when the provider or patient care team fails to comply with such a request (provider abandonment). The overall specimen abandonment rate in this study was 11.2%, meaning that these patients received no result(s) for the test(s) originally ordered. The laboratory abandonment rate was lower (median rate ¼ 1.3%) than when the provider abandoned the specimen (median rate ¼ 5%), but still significant. Specimen abandonment rates were significantly higher for all nonstat tests and for urine specimens. The association with nonstat priority may be a simple function of lower clinical urgency and a decision to wait for the next routine phlebotomy session or next urine collection opportunity to recollect a rejected specimen. Higher overall abandonment of urine specimens is likely a reflection of the difficulty in having patients produce urine samples on demand or in recollecting catheter urine specimens. Another association with higher specimen abandonment, this time by the provider, was institutions that train pathology residents/ fellows. Similar to the longer specimen processing delay seen in the largest hospitals, the higher rate of provider specimen abandonment may be related to the complexity and communication challenges typical in academic medical centers. A troubling finding in this study was the very high rate of mislabeled specimens that were the result of allowing providers and other patient care team members to relabel Arch Pathol Lab Med Vol 138, August 2014 Specimen Rejection Karcher & Lehman 1007
6 specimens that were received in the laboratory improperly labeled. Of the participating institutions, 45% allow relabeling of blood specimens and 37% allow relabeling of urine specimens. Among the institutions allowing specimen relabeling, this was reported to be allowed at higher rates for incompletely labeled specimens, but 59% and 38% of participating institutions allow correction of mislabeled or unlabeled blood specimens, respectively. Among these institutions, the percentage allowing correction of mislabeled or unlabeled urine specimens was similar (57% and 36%, respectively). When asked to indicate how many relabeled specimens ultimately turned out to not be from the intended patient (ie, wrong specimen in container), respondents reported that 39% of such specimens had this outcome. Though this may represent a slight overestimate of the true risk of a wrong specimen in container collection event (since multiple blood tubes may have been collected at the same time, but given different accession numbers and thus considered separate events), the incidence of wrong blood in container in this study is clearly concerning. An interesting sidelight to this finding was the fact that those institutions that allow specimen relabeling reported no significant shortening of the specimen processing delay resulting from specimen rejection, although they did report a slightly lower rate of specimen abandonment by the provider. Thus, allowing specimen relabeling resulted in little measurable advantage, yet this practice clearly introduced an increased risk to patient safety. These findings represent a strong indictment of the practice of routinely allowing relabeling of improperly labeled specimens. This practice has been increasingly discouraged in recent years, 6 8 a recommendation convincingly reinforced by this study. In summary, specimen rejection leads to a high rate of recollection of specimens, including repeated phlebotomy and recatheterization for urine, causing discomfort and potential complications in the affected patients. A major consequence of specimen rejection is a significant delay in availability of test results, of particular importance with stat tests and a situation potentially made worse in large and/or teaching hospitals, where a higher number of critically ill patients typically receive care. Specimen rejection also leads to frequent abandonment of the test(s) originally ordered, more so with nonstat tests and urine specimens. Finally, the practice of allowing relabeling of improperly labeled specimens is associated with little clinical benefit but introduces a significant likelihood of specimen mislabeling and potential harm to the patient. If laboratories choose to allow relabeling of blood and urine specimens, they should construct their policy thoughtfully, considering the relative risks and benefits, and perhaps restrict relabeling to correction of only the simplest labeling defects. The policy should also address relabeling of specimens that either cannot be recollected (eg, surgical pathology specimens), or that cannot be recollected without potential harm to the patient (eg, cerebrospinal fluid or other body cavity fluid specimens, bone marrow aspirate/biopsy specimens). References 1. Jones BA, Meier F, Howanitz PJ. Complete blood count specimen acceptability: a College of American Pathologists Q-Probes study of 703 laboratories. Arch Pathol Lab Med. 1995;119(3): Jones BA, Calam RR, Howanitz PJ. Chemistry specimen acceptability: a College of American Pathologists Q-Probes study of 453 laboratories. Arch Pathol Lab Med. 1997;121(1): Stark A, Jones BA, Chapman D, et al. Clinical laboratory specimen rejection association with the site of patient care and patients characteristics: findings from a single health care organization. Arch Pathol Lab Med. 2007; 131(4): Zarbo RJ, Jones BA, Friedberg RC, et al. Q-Tracks: a College of American Pathologists program of continuous laboratory monitoring and longitudinal performance tracking. Arch Pathol Lab Med. 2002;126(9): The Joint Commission. National patient safety goals for jointcommission.org/standards_information/npsgs.aspx, Published October 22, Accessed May 1, Paxton A. Punching a hole in specimen ID errors. CAP Today. 2008;22(6): Dunn EJ, Moga PJ. Patient misidentification in laboratory medicine: a qualitative analysis of 227 root cause analysis reports in the Veterans Health Administration. Arch Pathol Lab Med. 2010;134(2): Astion M. Patient safety focus: mislabeled specimens. Clin Lab News. 2010; 36(1): Arch Pathol Lab Med Vol 138, August 2014 Specimen Rejection Karcher & Lehman
CAP Laboratory Improvement Programs. Utility of Repeat Testing of Critical Values. A Q-Probes Analysis of 86 Clinical Laboratories
CAP Laboratory Improvement Programs Utility of Repeat Testing of Critical Values A Q-Probes Analysis of 86 Clinical Laboratories Christopher M. Lehman, MD; Peter J. Howanitz, MD; Rhona Souers, MS; Donald
More informationJanuary Testing Delays and Spurious Results Caused by Improper Specimen Collection
January 2011 Testing Delays and Spurious Results Caused by Improper Specimen Collection Lauren Anthony, MD, MT(ASCP)SBB Medical Director, Allina Medical Laboratories Collecting a specimen may seem routine,
More informationCAP Laboratory Improvement Programs. Appropriateness of Plasma Transfusion
CAP Laboratory Improvement Programs Appropriateness of Plasma Transfusion A College of American Pathologists Q-Probes Study of Guidelines, Waste, and Serious Adverse Events Kirsten Alcorn, MD; Glenn Ramsey,
More information2008 CAP TODAY Q & A
2008 CAP TODAY Q & A Q. How often should we document hematology competencies to ensure consistency of morphologic observations for manual differentials and fluids? Should we do this every six months or
More informationDetermination of Delay in :flirn Around Time (TAT) of Stat Tests and its Causes: an AKUH Experience
Determination of Delay in :flirn Around Time (TAT) of Stat Tests and its Causes: an AKUH Experience F. Bilwani,I. Siddiqui,S. Vaqar ( Section of Chemical Pathology, Department of Pathology, Aga Khan University
More informationDelta Check Calculation Guide
Delta Check Calculation Guide National Technology 2017, All Rights Reserved By Senior Scientific Researcher, Asmaa Taher Table of Contents Definition... 2 Purpose... 2 Delta Check Research Studies... 2
More informationAnalysis of Turnaround Time by Subdividing Three Phases for Outpatient Chemistry Specimens
144 Available online at www.annclinlabsci.org Annals of Clinical & Laboratory Science, vol. 39, no. 2, 2009 Analysis of Turnaround Time by Subdividing Three Phases for Outpatient Chemistry Specimens Hee-Jung
More informationPresented by Marcelo Cardona, MT(ASCP) Johns Hopkins University
Presented by Marcelo Cardona, MT(ASCP) Johns Hopkins University Alert or critical values represent those assay results that require prompt, rapid clinical attention to avert significant study-participant
More informationSample Quality Assurance
Sample Quality Assurance Phlebotomy Association of Ireland AGM 2012 Julie Riordan BSc, HDip Arts, MSc, F.A.M.L.S. Talk Outline Quality Assurance (QA) Preanalytical Variables (PAVs) & Errors (PAEs) Effects
More informationSelecting and Interpreting Lab Results -
Selecting and Interpreting Lab Results - e.g chest pain e.g PT PTT in bleeding disorders; blood glucose in diabetes etc Test ordering- direct order entry by person requesting the test is best.
More informationPatient Preparation Unique patient preparation requirements are listed under each test in the Test Directory.
Specimen Collection Lab results are only as good as the specimen provided. Patient preparation, venipuncture technique, specimen handling, and transportation can all affect the quantity of results. Health
More informationI. Subject: Ionized Calcium (Ca++) Analysis Whole Blood
I. Subject: Ionized Calcium (Ca++) Analysis Whole Blood II. Method: i-stat III. Principle: A. Ca++: is measured by ion-selective electrode potentiometry. Concentrations are calculated from the measured
More informationSpecimen Collection Requirements. Test Name Specimen Type Storage Time Storage Conditions
1 Specimen Collection Requirements PURPOSE/PRINCIPLE: To outline proper specimen collection for molecular HLA testing, including tube type, minimum specimen amount, proper tube and requisition labeling,
More informationCAP Laboratory Improvement Programs. Comparative Analytical Costs of Central Laboratory Glucose and Bedside Glucose Testing
CAP atory Improvement Programs Comparative Analytical Costs of Central atory Glucose and Bedside Glucose Testing A College of American Pathologists Q-Probes Study Peter J. Howanitz, MD; Bruce A. Jones,
More informationPreanalytical errors and patient outcomes
Preanalytical errors and patient outcomes ANA-MARIA SIMUNDIC C L I N I C A L I N S T U T E O F C H EMIS T RY U N I V ERS IT Y H O S PITA L C ENTER S ES T R E M I LO S RDNIC E Z A G R EB, C R O AT IA It
More informationCLINICAL LABORATORY SERVICES
10. SPECIMEN ACCEPTANCE/ REJECTION 10.1. General guidelines Complete the request form legibly, using a ball point pen, and completely; include a contact number. Samples which are inadequately identified
More informationHematology & Coagulation Practicum Objectives CLS - 647
Hematology & Coagulation Practicum Objectives CLS - 647 The following objectives are to be completed by the student for successful completion of this clinical rotation. The objectives within the psychomotor
More informationTrauma-Informed Primary Care Initiative Learning Community
www. T h e N a t i o n a l C o u n c i l. o r g Trauma-Informed Primary Care Initiative Learning Community Domain 5: Data Collection and Performance Improvement February 9, 2016 Today s Presenters Tony
More informationSALEM HOSPITAL SALEM, OREGON 97309
SALEM HOSPITAL SALEM, OREGON 97309 Department: Phlebotomy TITLE: BLOOD COLLECTIONS, VENIPUNCTURE Area: Phlebotomy Effective Date: 04/01/96 Authored By: Cindy Humphrey, Diane Duncan Revised: 09/26/2000,
More informationMTN 015 SPECIMEN REVIEW. Gabriel Banda Core Lab Supervisor UNC Project, Lilongwe
MTN 015 SPECIMEN REVIEW Gabriel Banda Core Lab Supervisor UNC Project, Lilongwe Review of MTN 015 Study MTN 015 is a multi-site observational cohort study whose study population are women who seroconverted
More informationNecessity of Clinical Information in Surgical Pathology
Necessity of Clinical Information in Surgical Pathology A College of American Pathologists Q-Probes Study of 771 475 Surgical Pathology From 341 Institutions Raouf E. Nakhleh, MD; Gordon Gephardt, MD;
More informationMarch 12, Medical Marijuana Preliminary Consultation Online Survey Report and Analysis. Introduction:
March 12, 2014 Medical Marijuana Preliminary Consultation Online Survey Report and Analysis Introduction: The College s current Medical Marijuana policy is under review. As part of this review, the College
More informationQuality Specifications for POCT
Quality Specifications for POCT the patient journey perspective Christopher P Price Department of Clinical Biochemistry, University of Oxford, Oxford, UK Quality Specifications fit-for-purpose QUALITY
More informationFAQs about upcoming OPTN policy changes related to blood type determination, reporting, and verification.
FAQs about upcoming OPTN policy changes related to blood type determination, reporting, and verification. Why are we changing ABO policies when it s one of the safest things we do in medicine? Have patients
More informationSTANDARD OPERATING PROCEDURE FOR DETERMINING SPECIMEN SUITABILITY
STANDARD OPERATING PROCEDURE FOR DETERMINING SPECIMEN SUITABILITY 1.0 Principle 1.1 Define the criteria of pre-transfusion testing and specimen suitability. 2.0 Scope and Related Policies 2.1 The Transfusion
More informationTimeliness and Accuracy of Reporting Preliminary Blood Culture Results
Timeliness and Accuracy of Reporting Preliminary Blood Culture Results A College of American Pathologists Q-Probes Study of 65 Institutions Ron B. Schifman, MD; Frederick A. Meier, MD; Rhona J. Souers,
More informationMultiple studies are available concerning the use of
SPECIAL ARTICLE Evaluation of the Biosite Ò Quantitative Whole Blood D-dimer Assay and Comparison With the biomérieux VIDAS Ò D-dimer Exclusion Test Validation and Utility For Use in the Central Laboratory
More informationACHIEVING TRUE LEAN IN HEMATOLOGY WITH FULL AUTOMATION, INTEGRATION, & PAPERLESS SOLUTIONS
ACHIEVING TRUE LEAN IN HEMATOLOGY WITH FULL AUTOMATION, INTEGRATION, & PAPERLESS SOLUTIONS Mary Ann Burich-Boccia, MBA,MT(ASCP)SBB Who we are: Mercy Medical Center 476 bed hospital serving a 5 county area
More informationCAP Laboratory Improvement Programs. The Autopsy as a Performance Measurement Tool Diagnostic Discrepancies and Unresolved. clinical questions.
CAP Laboratory Improvement Programs The Autopsy as a Performance Measurement Tool Diagnostic Discrepancies and Unresolved Clinical Questions A College of American Pathologists Q-Probes Study of 2479 Autopsies
More informationPreventing Genetic Testing Order Errors With a Laboratory Utilization Management Program
AJCP /ORIGINAL ARTICLE Preventing Genetic Testing Order Errors With a Laboratory Utilization Management Program Patrick C. Mathias, MD, PhD, 1 Jessie H. Conta, MS, 2 Eric Q. Konnick, MD, 1 Darci L. Sternen,
More informationIt s a Gas! Issues in the Blood Gas Laboratory. D. Robert Dufour, MD, FCAP Consultant Pathologist VA Medical Center, Washington DC
It s a Gas! Issues in the Blood Gas Laboratory D. Robert Dufour, MD, FCAP Consultant Pathologist VA Medical Center, Washington DC Learning Objectives After participating in this session, you will be able
More informationEDUCATIONAL COMMENTARY ORAL ANTICOAGULANT THERAPEUTIC MONITORING AND POINT-OF-CARE TESTING
POINT-OF-CARE TESTING Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits click on Continuing Education on
More informationCME/SAM. An Examination of the Usefulness of Repeat Testing Practices in a Large Hospital Clinical Chemistry Laboratory
Clinical Chemistry / Repeat Testing Practices in Clinical Chemistry An Examination of the Usefulness of Repeat Testing Practices in a Large Hospital Clinical Chemistry Laboratory Carl O. Deetz, MD, PhD,
More informationStatistical Press Notice NHS referral to treatment (RTT) waiting times data August 2017
Thursday 12 October 2017 Statistical Press Notice NHS referral to treatment (RTT) waiting times data August 2017 NHS England released statistics today on referral to treatment (RTT) waiting times for consultant-led
More information2014 Continuing Compliance Master Series Best Practices in Alternative Assessment of Performance
2014 Continuing Compliance Master Series Best Practices in Alternative Assessment of Performance Brad S. Karon, MD, PhD, FCAP November 19, 2014 www.cap.org Today s Presenter Brad S. Karon, MD, PhD, FCAP
More informationStatistical Press Notice NHS referral to treatment (RTT) waiting times data July 2018
Thursday 13 September 2018 Statistical Press Notice NHS referral to treatment (RTT) waiting times data July 2018 NHS England released statistics today on referral to treatment (RTT) waiting times for consultant-led
More informationCases requiring intra-departmental or extra-departmental consultation
CMS ID/CMS QCDR ID: CAP 28 Title: Helicobacter pylori Status and Turnaround Time Specifications Description CAP QCDR Percentage of stomach biopsy cases with gastritis that addresses presence or absence
More informationSTATISTICAL PRESS NOTICE NHS REFERRAL TO TREATMENT (RTT) WAITING TIMES DATA JANUARY 2013
STATISTICAL PRESS NOTICE NHS REFERRAL TO TREATMENT (RTT) WAITING TIMES DATA JANUARY 2013 Data are published on consultant-led Referral to Treatment (RTT) waiting times for patients who were treated during
More informationClinical laboratory testing is a production system that
Seven Q-Tracks Monitors of Laboratory Quality Drive General Performance Improvement Experience From the College of American Pathologists Q-Tracks Program 1999 2011 Frederick A. Meier, MD, CM; Rhona J.
More informationClinical Laboratory Quality Practices When Hemolysis Occurs
Clinical Laboratory Quality Practices When Hemolysis Occurs Peter J. Howanitz, MD; Christopher M. Lehman, MD; Bruce A. Jones, MD; Frederick A. Meier, MD; Gary L. Horowitz, MD Context. Hemolyzed specimens
More informationTesting Blood Glucose at the Bedside in a Chronic Care Hospital
CHEMISTRY Robert M. Greendyke, MD F. Ronald Gifford, MT(ASCP) Testing Blood Glucose at the Bedside in a Chronic Care Hospital We can provide tests that are fast, inexpensive, or accurate. Pick two. Anonymous
More informationDetail PRINCIPLE: Body fluids other than blood and urine will be analyzed according to their site of origin, and the providers specific orders.
Subject Body Fluid Analysis - Affiliate Index Number Lab-8760 Section Laboratory Subsection Regional/Affiliates Category Departmental Contact Munson, Karen Last Revised 6/28/2017 References Required document
More informationUse of PSI on CS instruments
Johan Claes, Version 01, 1 st September 2016 User day hemostasis 2016 Use of PSI on CS instruments Restricted Siemens Healthcare GmbH, 2016 Hemostasis Lab Challenges Preanalytical problems in Haemostasis
More informationPhlebotomy Skills and Experience
Western Technical College 10513107 Phlebotomy Skills and Experience Course Outcome Summary Course Information Description Career Cluster Instructional Level Total Credits 3 Total Hours 117 The phlebotomy
More informationImaging Performance Partnership. A Data Driven Approach to Your Imaging Program Strategy
Imaging Performance Partnership A Data Driven Approach to Your Imaging Program Strategy PROGRAM GOALS Imaging Performance Partnership has a wide array of tools to support various aspects of imaging business
More informationHISTOPATHOLOGY. Introduction
HISTOPATHOLOGY Introduction Contacts Services offered Pathology tissue request Laboratory hours Special instructions Histopathology reports List of specimens Introduction The Histopathology section of
More informationStatistical Press Notice NHS referral to treatment (RTT) waiting times data July 2017
Thursday 14 September 2017 Statistical Press Notice NHS referral to treatment (RTT) waiting times data July 2017 NHS England released statistics today on referral to treatment (RTT) waiting times for consultant-led
More informationQuantitative Image Analysis of HER2 Immunohistochemistry for Breast Cancer
Quantitative Image Analysis of HER2 Immunohistochemistry for Breast Cancer Guideline from the College of American Pathologists Early Online Release Publication: Archives of Pathology & Laboratory Medicine
More informationProvidence Medford Medical Center Pathology Department
Providence Medford Medical Center Pathology Department Anatomic pathology services including histology, cytology and autopsies are offered through Providence Medford Medical Center Pathology Department.
More informationLessons learned from accidents in conventional external radiotherapy
Lessons learned from accidents in conventional external radiotherapy Ola Holmberg 1,2, Renate Czarwinski 2 1 Radiation Protection of Patients Unit 2 Radiation Safety and Monitoring Section Division of
More informationTRANSFUSION REACTION EVALUATION
Lab Dept: Test Name: Transfusion Services TRANSFUSION REACTION EVALUATION General Information Lab Order Codes: Synonyms: CPT Codes: Test Includes: TRXR Transfusion Complication Workup; Hemolytic reaction
More informationPTA 240 PTA Clinical Education III Clinical Performance Instrument
Mercer County Community College Physical Therapist Assistant Program PTA 240 PTA Clinical Education III Clinical Performance Instrument Student/learner Dates of Clinical Experience Name of Clinical Site:
More informationPTA 235 PTA Clinical Education II Clinical Performance Instrument
Mercer County Community College Physical Therapist Assistant Program Learner PTA 235 PTA Clinical Education II Clinical Performance Instrument Dates of Clinical Experience Name of Clinical Site: Address:
More informationMedXellence Medical Incident Analysis: Group Exercise. Guidance Materials for the Patient Safety Video Presentation
MedXellence Medical Incident Analysis: Group Exercise Guidance Materials for the Patient Safety Video Presentation In this exercise you will observe a clinical/administrative sequence of events that that
More information6.1 Extended family screening
CHAPTER 6 CONCLUSION Cost benefit analysis of thalassemia screening programs have shown that the single years treatment for a β-thalassemia major patient was much higher than a total cost per case prevented.
More informationLaboratory Results Timeliness as a Quality Attribute and Strategy
Laboratory Results Timeliness as a Quality Attribute and Strategy Joan H. Howanitz, MD, and Peter J. Howanitz, MD Key Words: Turnaround time; Strategy; Quality improvement Abstract Although timeliness
More informationSAMED Position: Reuse of SUDs
SAMED Position: Reuse of SUDs What We Will Cover SAMED - who we are and what we do Definition of single-use device Overview of single-use device reprocessing Overview of SA and other countries regulatory
More informationTHE RELIABILITY OF EYEWITNESS CONFIDENCE 1. Time to Exonerate Eyewitness Memory. John T. Wixted 1. Author Note
THE RELIABILITY OF EYEWITNESS CONFIDENCE 1 Time to Exonerate Eyewitness Memory John T. Wixted 1 1 University of California, San Diego Author Note John T. Wixted, Department of Psychology, University of
More informationCleveland Clinic Laboratories. Trust in us for everything you need in a reference lab.
Cleveland Clinic Laboratories Trust in us for everything you need in a reference lab. 2 Cleveland Clinic Laboratories At Cleveland Clinic Laboratories, we recognize the results we turn out are pivotal
More informationLaboratory management of haemolysed samples results of an RCPAQAP survey. Penny Petinos
Laboratory management of haemolysed samples results of an RCPAQAP survey Penny Petinos Agenda Background to KIMMS survey on haemolysis Results of the 2010 and 2014 surveys Outcomes/decisions 2 Background
More informationSue Jung Kim, MD, MS; Yoonjung Kim, MD; Saeam Shin, MD; Jaewoo Song, MD, MS; Jong Rak Choi, MD, PhD
Comparison Study of the Rates of Manual Peripheral Blood Smear Review From 3 Automated Hematology Analyzers, Unicel DxH 800, ADVIA 2120i, and XE 2100, Using International Consensus Group Guidelines Sue
More informationStatistical Press Notice NHS referral to treatment (RTT) waiting times data November 2016
Statistical Press Notice NHS referral to treatment (RTT) waiting times data November 2016 NHS England released statistics today on referral to treatment (RTT) waiting times for consultant-led elective
More informationUse of PSI on CS instruments
Johan Claes, Version 01, 1 st September 2016 User day hemostasis 2016 Use of PSI on CS instruments Restricted Siemens Healthcare GmbH, 2016 Hemostasis Lab Challenges Preanalytical problems in Haemostasis
More informationHematology Measure #1: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow
Hematology Measure #1: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow This measure may be used as an Accountability measure Clinical Performance
More informationChanges in Automated Complete Blood Cell Count and Differential Leukocyte Count Results Induced by Storage of Blood at Room Temperature
Changes in Automated Complete Blood Cell Count and Differential Leukocyte Count Results Induced by Storage of Blood at Room Temperature Gene L. Gulati, PhD; Lawrence J. Hyland, MD; William Kocher, MD;
More informationSeventy percent of people who are candidates for allogeneic hematopoietic
274 7th Biennial Symposium on Minorities, the Medically Underserved and Cancer Supplement to Cancer The National Marrow Donor Program Meeting the Needs of the Medically Underserved Dennis L. Confer, M.D.
More informationFifty ways to fail your patient. Haemolytic transfusion reactions
Fifty ways to fail your patient Haemolytic transfusion reactions Nearly Fifty ways to fail your patient Haemolytic transfusion reactions Acute haemolytic transfusion reaction (AHTR): definition Fever and
More informationChristopher Okunseri, BDS, MSc, MLS, DDPHRCSE, FFDRCSI, Elaye Okunseri, MBA, MSHR, Thorpe JM, PhD., Xiang Qun, MS.
Dental Health Services Research Team Christopher Okunseri, BDS, MSc, MLS, DDPHRCSE, FFDRCSI, Elaye Okunseri, MBA, MSHR, Thorpe JM, PhD., Xiang Qun, MS., Aniko Szabo, PhD Research Support: National Institute
More informationSE Coast Cervical Screening QARC Interim Guidance for laboratories on cervical sample acceptance
SE Coast Cervical ing QARC Interim Guidance for laboratories on cervical sample acceptance List of accepted reasons/categories for sample rejection and inadequate cytology reports in SE Coast Version 6,
More informationISO IVD 13485: : :2015
ISO ISO 15197:2013 9001:2015 ISO 13485:2016 IVD Table of Contents Important Information About Your Gluco Spark Monitoring System... 1 Important Health-Related Information... 1 Alternate Test Site... 2
More informationMyelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data
Instructions for Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data (Form 2114) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the Myelodysplasia/Myeloproliferative
More informationCAP Laboratory Improvement Programs. Delta Check Practices and Outcomes
CAP Laoratory Improvement Programs Delta Check Practices and Outcomes A Q-Proes Study Involving 49 Health Care Facilities and 6541 Delta Check Alerts Ron B. Schifman, MD; Michael Talert, MD; Rhona J. Souers,
More informationPush Partner Registry Guide A healthcare provider s guide to provider-based distribution of pandemic influenza vaccine in Kent County
Push Partner Registry Guide A healthcare provider s guide to provider-based distribution of pandemic influenza vaccine in Kent County A Supplement to the Kent County Health Department Pandemic Influenza
More informationRoutine, Every 2 hours, Starting today, If temperature greater than 38.5 C initiate Evaluation for Possible Sepsis Physician Order #829
Height Weight Allergies General Vital Signs [X] Frequent vital signs Indication: Q15 minutes x (# of occurrences): 4 Q30 minutes x (# of occurrences): 4 Q1 hour x (# of occurrences): Q2 hours x (# of occurrences):
More informationPROTECTING THE SPORT: GUIDE TO FEDERATION RULE ENFORCEMENT AND HEARING PROCESS
PROTECTING THE SPORT: GUIDE TO FEDERATION RULE ENFORCEMENT AND HEARING PROCESS COVER PHOTO:SHAWN MCMILLEN INTRODUCTION This pamphlet has been drafted to provide general information and to help you understand
More informationThe most current laboratory testing information can be obtained at
About Adventist Lab Partners Reference Laboratory Adventist Lab Partners (ALPs) Reference Laboratory is affiliated with Adventist Health System. Adventist Lab Partners has been a hospital-based laboratory
More informationMonitoring the Health of Transplanted Organs DONOR GENOTYPING MANUAL
Monitoring the Health of Transplanted Organs DONOR GENOTYPING MANUAL 10101 Innovation Drive. Suite 600. Wauwatosa, WI 53226 1-888-214-3151 MKT-008 v3.0 MKT-008 v3.0 TABLE OF CONTENTS I Intended Use...
More informationPennsylvania Autism Needs Assessment
Pennsylvania Autism Needs Assessment A Survey of Individuals and Families Living with Autism Report #1: Pennsylvania Department of Public Welfare Bureau of Autism Services Needs Assessment Overview The
More informationAny questions or feedback, please or
LAB RESULTS REVIEW & REPORTING PROJECT CUMULATIVE LR 3 EVALUATION Last updated 2017-Mar-22 CONTENTS 1. Project objectives...1 2. Evaluation indicators...2 3. Baseline data...3 3.1 Total number of post-discharge
More informationPart II Rejected and miscollected samples. M.F Murphy & B.Stearn
Collection of Blood Samples (COBS) data collection carried out on behalf of the International Society of Blood Transfusion (ISBT) Biomedical Excellence for Safer Transfusion (BEST) Committee Part II Rejected
More informationCOLLECTION TUBES FOR PHLEBOTOMY
COLLECTION TUBES FOR PHLEBOTOMY Red Top None Blood clots, and the serum is separated by centrifugation Chemistries, Immunology and Serology, Blood Bank (Crossmatch) Gold Top None Serum separator tube (SST)
More informationMeasure #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clincial Care
Measure #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clincial Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY DESCRIPTION: Percentage
More informationBook Review: The Whale Done! School 1
Book Review: The Whale Done! School 1 Book Review: The Whale Done School Transforming a School s Culture by Catching Students Doing Things Right Jennifer Aiello Administrative Internship II Dr. Virginia
More informationPTA 240 PTA Clinical Education III Student Self Performance Evaluation Instrument
Mercer County Community College Physical Therapist Assistant Program PTA 240 PTA Clinical Education III Student Self Performance Evaluation Instrument Student/learner Dates of Clinical Experience Name
More informationDevelopment of the Nation-Wide Dosimetric Monitoring Network in Ukraine
Development of the Nation-Wide Dosimetric Monitoring Network in Ukraine V.Chumak 1, A.Boguslavskaya 2, A.Musijachenko 1 1 Scientific Center for Radiation Medicine AMS Ukraine, 04050 Melnikova, 53, Kiev,
More informationRitu Nayar, MD Professor and Vice Chair of Pathology Northwestern University, Feinberg School of Medicine Chicago, IL
Ritu Nayar, MD Professor and Vice Chair of Pathology Northwestern University, Feinberg School of Medicine Chicago, IL email: r-nayar@northwestern.edu Nothing to disclose College of American Pathologists
More informationDepartment of Neurology and Neurosurgery & Neuropathology Clinical Research Fellowship ONE YEAR FELLOWSHIP
Department of Neurology and Neurosurgery & Neuropathology Clinical Research Fellowship ONE YEAR FELLOWSHIP Type of Fellowship: Neuromuscular Pathology Name of the Fellowship Supervisors: Dr. Erin O Ferrall
More informationIRB policy and procedures 1. Institutional Review Board: Revised Policy and Procedures Elmhurst College
IRB policy and procedures 1 Institutional Review Board: Revised Policy and Procedures Elmhurst College IRB policy and procedures 2 Table of Contents A. Purpose and objectives... p. 3 B. Membership of the
More informationVeriFit Irritant Smoke Generators for Respirator Fit Testing SENSITIVITY CHECK PROTOCOL. Introduction. Warnings
VeriFit Irritant Smoke Generators for Respirator Fit Testing SENSITIVITY CHECK PROTOCOL Introduction This protocol is provided to you to be used in conjunction with normal irritant smoke fit test procedures
More informationLow Tolerance Long Duration (LTLD) Stroke Demonstration Project
Low Tolerance Long Duration (LTLD) Stroke Demonstration Project Interim Summary Report October 25 Table of Contents 1. INTRODUCTION 3 1.1 Background.. 3 2. APPROACH 4 2.1 LTLD Stroke Demonstration Project
More informationMODULE 6 WORK CULTURE AND LEADERSHIP ETHICS
MODULE 6 WORK CULTURE AND LEADERSHIP ETHICS Ed RANDELL CONTENTS OF THIS MODULE Ethics and Laboratory Medicine Defining Ethical Leadership The Foundations of Ethical Leadership in the Clinical Laboratory
More informationFrequently Asked Questions
Frequently Asked Questions These were updated on March 2018. 1. Details of revised Scheme from 4 April 2018 We are retaining the higher level of award ( 1,000) for childminders who care for children with
More informationPTA 235 PTA Clinical Education II Self Performance Evaluation Instrument
Mercer County Community College Physical Therapist Assistant Program PTA 235 PTA Clinical Education II Self Performance Evaluation Instrument Learner Dates of Clinical Experience Name of Clinical Site:
More informationPathology Student Interest Group. Sponsored by the College of American Pathologists
Pathology Student Interest Group Sponsored by the College of American Pathologists Pathology Right Now, A Pathologist Somewhere Is. Evaluating Surgical Specimens Diagnosis and Staging of Cancer Adequacy
More informationWOMEN & INFANTS HOSPITAL Providence, RI CONSENT FOR IN VITRO FERTILIZATION USING A GESTATIONAL CARRIER (PATIENT/INTENDED PARENTS) 1.
*40675* 40675 MR-838 (9-2017) WOMEN & INFANTS HOSPITAL Providence, RI 02905 CONSENT FOR IN VITRO FERTILIZATION USING A GESTATIONAL CARRIER (PATIENT/INTENDED PARENTS) 1. I, and (Print Patient s name) (Print
More informationConversion Guide. UNIT I THE HEALTHCARE SETTING 1 2 UNIT I THE HEALTHCARE SETTING Past And Present And The
UNIT I THE HEALTHCARE SETTING 1 2 UNIT I THE HEALTHCARE SETTING 1 2 1 Past And Present And The 3 38 1 Phlebotomy: Past And Present And 3 34 Healthcare Setting The Healthcare Setting Phlebotomy: A Historical
More informationMAINTAINING COMPLIANCE IN GLAUCOMA PATIENTS. by : Abdalla El-Sawy, M.D. Professor of Ophthalmology, Benha Faculty of Medicine.
MAINTAINING COMPLIANCE IN GLAUCOMA PATIENTS by : Abdalla El-Sawy, M.D. Professor of Ophthalmology, Benha Faculty of Medicine. The problem is especially critical for eye doctors who manage patients with
More informationStory Time Language Program Summary Child Language Intervention Program Vanderbilt University
Story Time Language Program Summary 2012-2013 Principal Investigator: Stephen Camarata, Ph.D. Child Language Intervention Program Vanderbilt University Researcher Biography Stephen Camarata, PhD Dept of
More information2016 Report Card Gwen Neilsen Anderson Rehabilitation Center Inpatient Rehabilitation Unit. stlukesonline.org
2016 Report Card Gwen Neilsen Anderson Rehabilitation Center Inpatient Rehabilitation Unit stlukesonline.org Why the Gwen Neilsen Anderson Rehabilitation Center? The Gwen Neilsen Anderson Rehabilitation
More informationTX CLPPP News. Important Survey Inside. Increasing Blood Lead Screening & Testing Rates in Texas Children
Texas Department of State Heatlh Services Childhood Lead Poisoning Prevention Program TX CLPPP News vol. 6, issue 2 Summer 2008 Increasing Blood Lead Screening & Testing Rates in Texas Children Over the
More information